Navigation Links
Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
Date:11/16/2012

MONTREAL, Nov. 16, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that the U.S. Federal Trade Commission (FTC) has completed its review of the proposed acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) by Valeant and has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) without conditions. The grant of early termination is effective as of November 15, 2012.

The proposed merger remains subject to other customary closing conditions, including the approval of the Medicis's stockholders at its special meeting of stockholders scheduled for December 7, 2012.  The Company expects to close the merger within four business days following satisfaction of all closing conditions.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

These forward-looking statements relate to, among other things, the expected timing of the close of the transaction.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "potential" and other similar expressions.  In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.  Actual results may differ materially from those expressed or implied in such statements.  Important factors that could cause actual results to differ materially from these expectations include, among other things, the expected timing of the close of the transaction and the satisfaction of the closing conditions to the transaction, and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"). 

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016 Zymo Research Corporation will ... at the American Urological Association,s Annual Meeting, the largest ... and isolates total DNA from a large volume of urine ... the company,s booth #5151 at the San Diego ... Conditioning Buffer ™ (UCB ™ ) that preserves ...
(Date:5/6/2016)... May 6, 2016 ReportsnReports.com ... 2016" to its database. The report provides comprehensive ... of the products at various stages of development. ... pipeline product development. It also provides information about ... trial status, trial start and end dates, and, ...
(Date:5/6/2016)... that we now stock the ( most advanced surgical and microscopic camera ) currently available, ... the consumer market in March 2016. Photo - http://photos.prnewswire.com/prnh/20160505/364465 ... ... ... GP-UH532 camera is the newest iteration of Panasonic,s 1080p HD camera and is part of ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... "ProIntro Music is a great new set of self-animating intros for Final ... ProIntro Music is a set of 30 self-animating introductions created exclusively for use in ... X editors to add a unique opener to any video production. Choose from dynamic ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Speech, hearing, and ... (ASHA). Since 1927, ASHA has celebrated Better Hearing and Speech Month each May ... Care. , “We live in an era full of technology. Kids spend hours ...
(Date:5/6/2016)... ... ... The team at Tijuana Bariatric Center is pleased to announce that the ... to bariatrics. , Thanks to this recent expansion, the network of bariatric surgeons ... looking for a solution to obesity and obesity-related illness. This means that the practice ...
(Date:5/6/2016)... , ... May 06, 2016 , ... With more than ... a part of the cosmetic team at South Jersey Skin Care & Laser Center, ... now working as the practice’s new licensed medical esthetician. , Dr. Robin Levin came ...
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association ... education initiative in Puerto Rico. Radio messages set to debut on Monday, May ... and pharmacists about ways to protect themselves and their unborn children from the ...
Breaking Medicine News(10 mins):